DelveInsight’s, “Peritoneal Cancer Pipeline Insight 2024” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Peritoneal Cancer pipeline landscape. It covers the Peritoneal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peritoneal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Peritoneal Cancer Research. Learn more about our innovative pipeline today! @ Peritoneal Cancer Pipeline Outlook

Key Takeaways from the Peritoneal Cancer Pipeline Report

• June 2024:- ImmunoGen Inc.- Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)
• June 2024:- Tesaro Inc.- A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
• June 2024:- K-Group, Beta, Inc.- A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (ZN-c3-005/GOG-3066/DENALI).
• DelveInsight’s Peritoneal Cancer pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Peritoneal Cancer treatment.
• The leading Peritoneal Cancer companies such as Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma, and others.
• Promising Peritoneal Cancer Therapies such as Bevacizumab, 131 I-omburtamab, Catumaxomab, Fulvestrant, Abemaciclib, Mirvetuximab soravtansine plus Bevacizumab, Pembrolizumab, MORAb-202, KAND567, and others.

Stay informed about the cutting-edge advancements in Peritoneal Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Peritoneal Cancer Clinical Trials Assessment

Peritoneal Cancer Emerging Drugs Profile

• Masitinib: AB Science

Masitinib is an orally administered tyrosine kinase inhibitor. It modulates the activity of mast cells and macrophages, important cells for immunity, through targeting a limited number of kinases without inhibiting, at therapeutic doses, kinases associated with known toxicities. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. Masitinib’s mechanism of action in peritoneal cancer involves inhibiting tumor growth by targeting specific kinases like KIT and PDGFR, crucial for cancer progression, without causing general toxicity. Currently, the drug is in Phase III stage of its clinical trial for the treatment of peritoneal cancer.

• Azenosertib: Zentalis Pharmaceuticals

Azenosertib is a potentially first-in-class and best-in-class small molecule Wee1 inhibitor in development for the treatment of cancer. Inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death. Currently, there are no FDA-approved WEE1 inhibitors, and we have designed Azenosertib to have advantages over other investigational therapies, including superior selectivity and pharmacokinetic properties. Currently, the drug is in Phase II stage of its clinical trial for the treatment of peritoneal cancer.

• IMGN151: ImmunoGen

IMGN151 is a next-generation ADC, designed to address the unmet needs of cancer patients with tumor types expressing lower levels of folate receptor alpha (FRα). IMGN151 comprises an asymmetric, bivalent, biparatopic antibody targeting two independent epitopes of FRα, linked to a highly potent maytansinoid derivative, DM21, via a cleavable peptide linker with enhanced stability, longer half-life, and increased bystander activity. Currently, the drug is in Phase I stage of its clinical trial for the treatment of peritoneal cancer.

Learn more about Peritoneal Cancer Drugs opportunities in our groundbreaking Peritoneal Cancer Research and development projects @ Peritoneal Cancer Unmet Needs

Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Peritoneal Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Peritoneal Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Peritoneal Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Peritoneal Cancer Pipeline Report

• Coverage- Global
• Peritoneal Cancer companies- Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma, and others.
• Peritoneal Cancer Therapies- Bevacizumab, 131 I-omburtamab, Catumaxomab, Fulvestrant, Abemaciclib, Mirvetuximab soravtansine plus Bevacizumab, Pembrolizumab, MORAb-202, KAND567, and others.
• Peritoneal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Peritoneal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Peritoneal Cancer Pipeline on our website @ Peritoneal Cancer Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Peritoneal cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peritoneal cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Masitinib: AB Science
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Azenosertib: Zentalis Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. IMGN151: ImmunoGen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Peritoneal cancer Key Companies
21. Peritoneal cancer Key Products
22. Peritoneal cancer- Unmet Needs
23. Peritoneal cancer- Market Drivers and Barriers
24. Peritoneal cancer- Future Perspectives and Conclusion
25. Peritoneal cancer Analyst Views
26. Peritoneal cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/